ASH Annual Meeting and Exposition | Conference

Zanubrutinib Showcases Sustained PFS Benefit Vs Ibrutinib in R/R CLL/SLL

December 10th 2023

Zanubrutinib continued to demonstrate improved progression-free survival benefit over ibrutinib in the treatment of patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, according to extended follow-up data from the phase 3 ALPINE trial.

Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL

December 10th 2023

Michael R. Cook, MD, discusses real-world data associated with the utilization of bridging therapy prior to treatment with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.

Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL

December 10th 2023

Andre Goy, MD, discusses outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma enrolled in the phase 2 ZUMA-2 trial and the expanded access ZUMA-18 study.

Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma

December 9th 2023

Idecabtagene vicleucel resulted in meaningful improvements in symptoms, functioning, overall health status, and health-related quality of life vs standard regimens in select patients with triple-class exposed relapsed/refractory multiple myeloma, according to updated data from the phase 3 KarMMa-3 trial.

Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL

December 9th 2023

Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.

Brexu-Cel Induces Responses in Real-World Population of High-Risk R/R MCL

December 9th 2023

Brexucabtagene autoleucel is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

Revumenib Combo Showcases Early Activity in Relapsed/Refractory AML

December 9th 2023

Revumenib, decitabine/cedazuridine, plus venetoclax elicited an objective response rate of 100% with acceptable safety in patients with relapsed/refractory acute myeloid leukemia enrolled in the small phase 1/2 SAVE study.

Real-World Analysis Sheds Light on Safety and Efficacy of Teclistamab in R/R Multiple Myeloma

December 9th 2023

The T-cell redirecting bispecific antibody teclistamab-cqyv demonstrated efficacy and a tolerable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma consistent with that of those enrolled in the phase 2 MajesTEC-1 trial.

AI Algorithm Effectively Differentiates Between pre-PMF/ET

December 9th 2023

A machine learning, artificial intelligence algorithm analyzing diagnostic bone marrow biopsy digital whole-slide images was able to effectively differentiate with 92.3% accuracy between prefibrotic primary myelofibrosis and essential thrombocythemia.

All-Oral Arsenic Trioxide, All-Trans Retinoic Acid/Ascorbic Acid Proves Effective, Safe in Acute Promyelocytic Leukemia

December 9th 2023

Treatment with an all-oral regimen of arsenic trioxide, all-trans retinoic acid, and ascorbic acid led to both 3-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia.

Dr. Cheah on the Investigation of BGB-11417 With or Without Zanubrutinib in CLL

December 16th 2022

Chan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.

Tisagenlecleucel Shows Promise in Relapsed/Refractory Aggressive B-Cell NHL and Comorbidities in Real-World Setting

December 15th 2022

Tisagenlecleucel elicited durable efficacy and a favorable long-term safety profile in the real-world setting of patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Olutasidenib Elicits Durable Responses in IDH1-Mutant, Relapsed/Refractory AML

December 14th 2022

Olutasidenib monotherapy induced high complete response rates with a manageable toxicity profile in patients with relapsed/refractory acute myeloid leukemia harboring IDH1 mutations.

Dr. Jim on Real-World Quality of Life Outcomes With Axi-Cel in R/R LBCL

December 14th 2022

Heather Jim, PhD, discusses a real-world analysis, examining the quality of life outcomes seen with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.

BGB-11417 Alone or in Combination with Zanubrutinib Shows Early Efficacy in CLL/SLL

December 13th 2022

BGB-11417, when given alone or in combination with zanubrutinib, elicited encouraging responses and minimal residual disease negativity rates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to preliminary data from a phase 1 trial.

Dr Reshef on Data From the BMT CTN 1703 Trial Evaluating Post-Transplant GVHD Prophylactic Regimens

December 13th 2022

Ran Reshef, MD, discusses findings from the phase 3 BMT CTN 1703 trial examining graft-vs-host disease prophylaxis in reduced intensity conditioning.

HD-ASCT Demonstrates Improved PFS Vs Non-Myeloablative Chemoimmunotherapy in Primary CNS Lymphoma

December 13th 2022

Consolidation therapy with high-dose chemotherapy and autologous stem cell transplantation improved progression-free survival vs non-myeloablative chemoimmunotherapy in patients with primary central nervous system lymphoma.

BCMA/CD19 Dual-targeting CAR T-cell Therapy Shows 100% MRD Negativity Rate in Newly Diagnosed Multiple Myeloma

December 13th 2022

Among patients with newly diagnosed high-risk multiple myeloma, treatment with BCMA/CD19 dual-targeting FasTCAR-T Cells resulted in an overall response rate of 100%, with all treated patients evaluable for minimal residual disease showing minimal residual disease negativity to 12 months.

Dr Peffault de Latour on the Benefit of Iptacopan Vs SOC in PNH and Residual Anemia

December 13th 2022

Regis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.

GVHD Prophylactic Regimen Improves 1-Year GRFS Vs Standard in Patients With Hematologic Malignancies Post-HCT

December 13th 2022

Administration of cyclophosphamide, tacrolimus, and mycophenolate mofetil improved 1-year GVHD relapse-free survival compared with tacrolimus plus methotrexate in patients with hematologic malignancies undergoing reduced intensity conditioning allogeneic hematopoietic cell transplantation.